Radiopharmaceutical therapy (RPT) development is a challenging process that requires collaboration with industry leaders to offer key insights and perspectives. Equipped with industry-leading scientific, regulatory and operational expertise, our RPT team drives and oversees all aspects of your project. From study design to analysis, our team empowers therapeutic decisions with high-quality imaging data across the research pipeline. 






Ed Hogan
Chief Operations Officer

Ed Hogan has over thirty years of experience in clinical research, managing and executing early Phase I through Phase 4 imaging trials in both the pharmaceutical and imaging CRO space. He has more than twenty years of experience in managing clinical operations, including extensive experience leading cross-functional teams, including Operations (Project, Image and Data Management), Engineering (Development and Validation) and Medical and Scientific Services.

Ed has progressive business experience in building and managing global cross-functional teams supporting clinical trials focusing teams on delivery, accountability, and customer satisfaction while driving quality and process improvements. As COO, Ed oversees Invicro’s primary Business Units (Clinical Services, Discovery and Preclinical Services, Advanced Pathology Services) as well as Clinic and Lab Services, Corporate Operations, Commercial Sales, and Quality and Regulatory.





Phillip Kuo, MD, PhD
Distinguished Scientist

Phillip Kuo M.D., PhD., F.A.C.R. graduated in chemistry from Harvard University and then earned an MD/PhD from University of Virginia. Post-graduate training included residencies in Internal Medicine at UCLA and Nuclear Medicine and Radiology at Yale. He previously served as Chief of Nuclear Medicine for 10 years at a university medical center. He has more than 100 peer-reviewed publications and has served as principal investigator and co-principal investigator on multiple NIH grants and investigator-initiated trials.

His experience includes design and supervision of Phase I-III clinical trials including theranostics with PET, SPECT, MRI and radiotherapeutics as well as leading the VISION read development. Additionally, Dr. Kuo has participated in USFDA and EMA meetings for regulatory approval. As a reader for clinical trials, he has reviewed over ten thousand scans for oncology and neurology.





Sean Carlin, PhD
Principal Scientist

Dr. Sean Carlin has >25 years of pre-clinical and translational radiopharmaceutical research experience and is an expert in radiation biology. Dr. Carlin also has a particular emphasis on the design and evaluation of radioligands and advanced pre-clinical nuclear imaging techniques. Dr. Carlin has more than 100 peer-reviewed publications and has served as principal investigator and co-principal investigator on multiple US federal grants and sponsored projects. Prior to joining Invicro, he held faculty positions at Weill-Cornell Medical Center, Memorial Sloan Kettering Cancer Center, and The University of Pennsylvania. Dr. Carlin holds a PhD in Molecular Radiopharmacology from the University of Glasgow, Scotland.





Ciara Finucane
VP, Discovery & Preclinical Services

Ms. Ciara Finucane joined Invicro in January 2013 and specializes in nuclear techniques, including the evaluation of molecular targets for radionuclide-mediated diagnosis and therapy of cancer. With over 15 years of experience, Ms. Finucane specializes in preclinical SPECT and PET imaging with a focus on the design, execution and project management of nuclear imaging studies.

Ms. Finucane received her honors degree in Physiology from Trinity College Dublin and her MSc in Forensic Sciences from Kings College London. Prior to Invicro, Ms. Finucane developed cancer therapeutic and imaging agents for the Center for Molecular Imaging at Bart's Cancer Institute at Queen Mary University of London.





Jan Passchier, PhD
EVP, Global Head of Labs & Clinics

Dr. Jan Passchier is a radiochemistry expert who specializes in imaging and drug development. He holds a PhD in PET radiochemistry from Groningen University. Dr. Passchier started his career at GlaxoSmithKline where he identified and developed novel tool compounds for a large variety of CNS, metabolic and respiratory indications.

Dr. Passchier played a significant role in the design and realization of the GlaxoSmithKline Clinical Imaging Centre where he headed the chemistry group. Following a spin-out of the center to Imanova Ltd, now part of Invicro, his role expanded to include operational responsibility for the business. Dr. Passchier has a keen interest and deep understanding of the application of molecular imaging to disease understanding and drug development.





Beth Rodriguez
VP, Project Management

Ms. Beth Rodriguez oversees the project management team to ensure adequate resource management, streamlined timelines and efficient and effective client communication. She has more than 15 years of international clinical research and over 20 years of imaging experience. Ms. Rodriguez successfully managed over 100 large-scale global clinical studies which include various oncology indications from Phase I-III. She excels at managing and leading remote internal and external team members across service lines. In addition, Ms. Rodriguez has participated in and supported regulatory and client audits (FDA, PMEA). Prior to joining Invicro, Ms. Rodriguez worked as an Operational Head for more than 5 Sponsor Governance committees.

Interested in learning more?